They stated around 70% of the costs would be funded via debt facilities, so not a massive dilution if they raise capital through share placement for the rest.
That's assuming they fund everything themselves but as also mentioned in the study there is the potential for JVS and sale etc
- Forums
- ASX - By Stock
- IXR
- Ann: Makuutu Rare Earths Project Scoping Study
Ann: Makuutu Rare Earths Project Scoping Study, page-31
-
- There are more pages in this discussion • 373 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXR (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
-0.001(9.09%) |
Mkt cap ! $48.31M |
Open | High | Low | Value | Volume |
1.1¢ | 1.1¢ | 1.0¢ | $176.2K | 17.44M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1420000 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 5195747 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 1420000 | 0.010 |
37 | 19465575 | 0.009 |
13 | 7190627 | 0.008 |
10 | 6457314 | 0.007 |
7 | 6085000 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 5195747 | 5 |
0.012 | 5662901 | 16 |
0.013 | 3314749 | 6 |
0.014 | 2909137 | 7 |
0.015 | 1769733 | 7 |
Last trade - 15.21pm 15/07/2024 (20 minute delay) ? |
Featured News
IXR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online